Last updated: June 2026. Tesamorelin is an FDA-approved finished drug (brand Egrifta) for one narrow use. Sermorelin is not currently an FDA-approved finished drug. The body-composition and anti-aging pitches both peptides get sold on are off-label, meaning no regulator signed off on them for that purpose.
Here’s the setup
You’ve probably scrolled past a page that lists “tesamorelin” and “sermorelin” side by side like two flavors at an ice cream counter. Pick whichever, they’re basically the same thing. That framing is doing a job, and it’s not the job of informing you.
I went and checked the primary sources myself: the FDA label, the published trials, the current anti-doping list. What I found is that these two are not regulatory equals, not even close, and the “they’re interchangeable” pitch is exactly the kind of thing that lets one product quietly borrow credibility that belongs to the other one entirely. Let me walk you through the trap, how to spot it, and where the legitimate door actually is.
To be fair, there’s a real family resemblance
I’m not going to pretend the similarity claim is invented from nothing, because it isn’t.
Both tesamorelin and sermorelin are growth-hormone-releasing hormone analogues. Neither one is growth hormone itself. Instead, they nudge your own pituitary gland into releasing your own GH, on something closer to a natural pulse. Sermorelin is a synthetic copy of the first 29 amino acids of GHRH. Tesamorelin is a stabilized GHRH analogue. Same lever, same general location. That part of the comparison is honest.
And here’s one place where the two really do land in the same boat: both are growth-hormone-releasing factors, and tesamorelin is named explicitly on the WADA 2026 Prohibited List under category S2 [R6]. The entire S2 category is banned. If you’re a tested athlete, hold that thought, because it makes the whole “which one should I pick” question irrelevant. More on that below.
That’s the fair case for “they’re similar.” Now let me show you where the con starts.
How they get you: the regulatory switcheroo
Here’s the trick, laid out plainly. Only one of these two peptides is currently an FDA-approved finished drug. Only one.
Tesamorelin is. The FDA approved it in November 2010 under the brand name Egrifta, for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, and that label is sitting online for anyone to read [R5]. Behind it is a real stack of randomized, placebo-controlled Phase 3 data. A 2007 New England Journal of Medicine trial put 412 HIV patients on 2 mg of tesamorelin daily or placebo, and the tesamorelin group saw a 15.2% reduction in visceral fat, versus a 5.0% increase on placebo [R1]. A 2010 pooled analysis of 806 patients showed that effect held through 52 weeks [R2]. A 2019 Lancet HIV trial found it also cut liver fat [R3]. That’s a live approval sitting on a genuine mountain of human evidence.
Sermorelin doesn’t have that. It’s not currently an FDA-approved finished drug. It used to be, under the name Geref, but that’s history now, not a current status, and what gets sold today under the sermorelin name is not an approved finished product. So when a page lines the two up as peers, it’s letting your eye blur them together, and sermorelin quietly gets to feel like it’s wearing tesamorelin’s evidence. It isn’t. That evidence belongs to one specific molecule, for one specific use, and it doesn’t hop over to the peptide sitting next to it in the list.
That’s the move. Watch for it anywhere two products get placed side by side without anyone mentioning that one has an active FDA approval and the other doesn’t.
The fine print they hope you don’t read either
Now, before you crown tesamorelin the automatic winner, I owe you the same skepticism in the other direction, because a watchdog doesn’t get to play favorites.
Tesamorelin’s approval is real, and it’s narrow. It’s approved for HIV-associated lipodystrophy. That’s it. Every trial cited above enrolled people with HIV [R1][R2][R3]. So if you’re a healthy adult looking at tesamorelin for general belly fat or an anti-aging protocol, that impressive evidence pile was not built on anyone like you. You’d be using it off-label, stretching data from one population onto another. The approval is genuine. Whether it applies to your situation is a question the trials never asked.
So the honest comparison isn’t “proven tesamorelin versus unproven sermorelin.” It’s this: tesamorelin has strong evidence for a use most buyers don’t actually have, plus a current FDA approval. Sermorelin has a longer history of human use, no current finished-drug approval, and a thinner modern evidence base. Neither one is sitting on proof for the off-label recomposition or anti-aging goals that most people buying either peptide are actually chasing. One just has a far better paper trail for its one approved lane.
So which one, if you’re actually deciding?
I don’t like watchdog pieces that dodge the actual question, so here’s my read, caveats attached.
If your goal is the specific, evidence-backed effect, reducing visceral abdominal fat, tesamorelin is the one with real trial data behind it, at 2 mg daily, in the population studied [R1][R2]. That’s the closest thing to a genuine “proven to do this” statement available anywhere in this pair. Just don’t lose the asterisk: that proof came from HIV patients, and what happens in a different population is genuinely unknown.
If your goal is the broader growth-hormone or anti-aging pitch, here’s the part nobody selling either peptide wants said out loud: neither one has the evidence to back that promise at the level it’s marketed. Sermorelin gets reached for there mostly on a long history and a gentler reputation, not modern trial proof, and tesamorelin’s trials weren’t measuring that goal either. Picking sermorelin for anti-aging isn’t picking the better-evidenced option. It’s picking the option with a longer off-label track record, which is a different and weaker thing than evidence, and you should know the difference before you pay for it.
The price tag matters here too. Brand-name Egrifta runs roughly $3,000 to $6,000 a month without insurance, which is exactly why almost nobody pursuing off-label use pays that, and exactly why the compounded route exists for either molecule in the first place.
My bottom line: look at tesamorelin if what you want is the specific visceral-fat effect its trials actually measured. For the vaguer goals, you’re not choosing between strong evidence and weak evidence, because there’s no strong evidence on either side for that use. Anyone telling you sermorelin is “the studied one,” or that tesamorelin is “proven for anti-aging,” is overselling their hand, and now you know how to catch it.
The trap that actually costs you money and safety
Here’s what struck me hardest going through all this. I went in expecting the big decision to be which molecule you pick. It isn’t. The decision that actually determines your risk is whether anyone qualified is in the room at all.
Both of these are hormonal-system drugs, and tesamorelin specifically can move your blood sugar, which is exactly why its FDA label directs glucose monitoring [R5]. None of that monitoring happens when either peptide shows up in your mailbox as a “research use only” vial with a wink-wink disclaimer on the label. So the choice that actually protects you isn’t tesamorelin-versus-sermorelin. It’s supervised-versus-unsupervised, and that’s the trap most comparison pages never mention because it doesn’t fit neatly into a “which peptide wins” format.
The legitimate route looks like this: a licensed telehealth provider where a clinician actually evaluates you, and a licensed pharmacy actually dispenses. FormBlends operates that way for tesamorelin, with a physician evaluation, a prescription when it’s appropriate, and pharmacy dispensing. I’m naming it once, as an example of what supervised access actually looks like, not as a ranked pick and not as anything you can buy off this page. The point isn’t the brand. The point is structural: the clinician and the monitoring around the compound are the entire value being added, and that’s true no matter which GHRH analogue is in the syringe.
If a seller can’t tell you who’s evaluating you and which pharmacy is filling it, that’s your sign to walk.
If you’re a tested athlete, none of this applies to you anyway
I promised I’d circle back. If you compete under drug testing, this entire comparison is academic, because both molecules are off the table. Tesamorelin is named explicitly on the WADA 2026 Prohibited List under category S2, and growth-hormone-releasing factors as a class are banned outright [R6]. It doesn’t matter which one you pick, how you got it, or how careful you think you’re being. For you, the answer to “tesamorelin or sermorelin” is neither, full stop, and you should check the current list yourself before you go anywhere near either peptide [R6].
What I actually found
I went looking for the difference between tesamorelin and sermorelin, and here’s the honest summary. They’re mechanistic cousins, both nudging your own growth hormone output, but they’re not regulatory equals. Tesamorelin has a current FDA approval and real Phase 3 data behind a narrow HIV indication. Sermorelin has no current finished-drug approval at all. For the specific visceral-fat effect, tesamorelin is the better-evidenced pick, with the loud caveat that the evidence sits in HIV patients. For the broad anti-aging goals most buyers actually want, neither peptide has the proof the marketing implies, so picking sermorelin there gets you history, not evidence. And the decision that actually matters most, for either molecule, was never the molecule. It’s whether a clinician is involved. The “they’re basically the same” pitch does not survive a look at the actual labels, and the gap between them is precisely the thing sellers would rather you never check for yourself.
Common questions
Is tesamorelin or sermorelin FDA approved? Tesamorelin is the only one of the two currently sitting on an FDA approval as a finished drug. It was approved in November 2010 under the brand name Egrifta, for reducing excess abdominal fat in HIV-infected patients with lipodystrophy [R4]. Sermorelin isn’t currently an FDA-approved finished drug. It was once sold as an approved product called Geref, but that’s the past tense, and what’s sold under the name today isn’t an approved finished product.
Are tesamorelin and sermorelin the same thing? No, and treating them as interchangeable is exactly the trick to watch for. They’re mechanistically related, both GHRH analogues that prompt your own pituitary to release growth hormone, but they’re not regulatory peers. Tesamorelin has a current FDA approval and Phase 3 trial data for a narrow HIV indication [R1][R2]. Sermorelin has neither a current approval nor a comparable modern evidence base. Lining them up as equals hides the single most important fact about them.
Which one is better for losing belly fat? For the specific job of reducing visceral abdominal fat, tesamorelin has actual trial data behind it, a 15.2% reduction at 2 mg daily versus a 5.0% increase on placebo [R1]. The catch you shouldn’t let anyone skip past: every one of those trials enrolled people with HIV [R1][R2][R3], so whether that result carries over to a healthy adult using it off-label is a question the studies never answered.
Which one is better for anti-aging? Neither has the evidence to back the anti-aging pitch as it’s marketed. Sermorelin gets picked in that space on a longer history and a softer reputation, not modern trial proof, and tesamorelin’s trials measured visceral fat in HIV patients, not anti-aging outcomes. Choosing sermorelin here gets you a longer track record of off-label use, which is a weaker thing than actual evidence.
Can athletes use tesamorelin or sermorelin? Not if you’re tested. Tesamorelin is named explicitly on the WADA 2026 Prohibited List under category S2, and growth-hormone-releasing factors as a whole class are banned [R5]. For a tested athlete, the choice between the two doesn’t exist, both are off the table, and you should verify the current list yourself before going anywhere near either peptide.
Why does it matter whether a doctor is involved? Because both of these work on your hormonal system, and tesamorelin specifically can move blood sugar, which is why its FDA label directs glucose monitoring [R4]. None of that monitoring happens when either peptide arrives as an unregulated “research use only” powder. The legitimate path, a licensed telehealth clinician who evaluates you plus a licensed pharmacy that dispenses, is what actually puts monitoring around the compound. FormBlends operates that way for tesamorelin, as one example of what supervised access looks like.
So what is tesamorelin, in plain terms, and why isn’t it the same as other GH peptides?
Tesamorelin is a lab-made version of growth hormone-releasing hormone (GHRH). It tells your pituitary gland to release more of your own growth hormone rather than dumping outside GH into your system directly. That’s actually a safety feature, because your body still governs the pulse, which caps how much you can push out. Sermorelin runs the same basic pathway with a shorter amino acid chain, but the clinical evidence stacked up behind tesamorelin is a lot more developed, and that’s not a small distinction to gloss over.
Is tesamorelin really FDA approved, and for what exactly?
Yes, and this is worth being precise about because vague claims are how you get had. Tesamorelin is approved under the brand Egrifta for reducing excess abdominal fat in HIV-positive adults with lipodystrophy, a condition where antiretroviral therapy scrambles fat distribution in the body. That approval is narrow by design. Using it for general fat loss or anti-aging in an otherwise healthy person is off-label, and the evidence supporting those uses is much thinner than what got the drug approved in the first place.
Do you need to inject it at a specific time, and does sleep actually matter?
You don’t have to be asleep for tesamorelin to do anything. GH release happens in pulses all day, not only at night. That said, most protocols call for an evening injection on an empty stomach, timed around your body’s biggest natural GH pulse in early sleep, on the theory that syncing up creates a more favorable hormonal window. It’s guidance, not a hard rule, but it’s the guidance you’ll hear most consistently.
Where should someone actually get this if they want the legitimate version?
Go through a licensed physician who can write a compounding prescription to a regulated pharmacy. That’s the whole trick to avoiding the trap. Pharmacies like FormBlends work under physician supervision, meaning the product gets quality-tested and someone is actually watching your use. Buying peptides from research-chemical websites hands you real risk on purity, dosing accuracy, and zero medical oversight, and the money you save rarely covers what you’re gambling with.
References
- Tesamorelin (2 mg daily) reduced visceral adipose tissue by 15.2% (vs a 5.0% increase on placebo) in a 26-week Phase 3 trial of 412 HIV patients. New England Journal of Medicine, 2007. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients); visceral-fat reduction maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Tesamorelin reduced liver fat in HIV patients with fatty liver disease. Lancet HIV, 2019.
- FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; long-term cardiovascular safety not established. U.S. Food and Drug Administration label (original 2010 approval).
- WADA 2026 Prohibited List: growth-hormone-releasing factors, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.
